TargetCancer Foundation is at the forefront of advancing rare cancer research.
Since our founding in 2009 by a patient facing cholangiocarcinoma, we have worked to speed the path to more effective and personalized rare cancer treatments through research. Our research initiatives engage key rare cancer stakeholders, including patients, advocates, researchers, clinicians, drug developers, and regulators. These initiatives include:
TRACK Clinical Trial
Funded Research Projects
Rare Cancer Scientific Meetings
Rare cancer publications
Read publications resulting from TCF funded research.
TCF-001 TRACK Clinical Trial
The TCF-001 TRACK clinical trial represents a cutting-edge approach in the field of precision oncology, specifically focusing on rare cancers and cancers of unknown primary. This trial is currently enrolling 400 patients using a remote consenting process. This process allows patients to conveniently enroll in the TRACK study from the comfort of their homes, eliminating the need for travel to clinical trial sites.
Once enrolled, patients gain access to biomarker testing of their tissue and blood at no cost, and the results of these tests are reviewed and interpreted by a multidisciplinary panel of esteemed clinicians and scientists specializing in rare cancers. This expert panel provides patients with individualized treatment recommendations, informed by the latest advancements in genomic research and personalized to their unique health needs.
I consider this THE national precision medicine trial for rare cancers.
Razelle Kurzrock, MD
Principal Investigator, TRACK
Froedtert and Medical College of Wisconsin
Since 2009,
we have invested more than $2 million in multi-year commitments
to targeted rare cancer research initiatives.
Rare Cancer Research Projects Funded by TCF
For more than 15 years, TargetCancer Foundation has supported the creation of rare cancer discovery tools and research collaborations that:
- Fill the gap in funding for publicly available research models, such as cell lines and mouse models;
- Improve understanding of driver mutations;
- Foster cross-institutional research collaborations;
- Drive discovery in cholangiocarcinoma and esophageal cancer;
- And much more.
Scientific Meetings
TargetCancer Foundation regularly convenes clinicians, researchers, industry, regulators, patient advocates, and patients to share insights and address common challenges in rare cancer treatment and care. The relationships formed at these highly interactive, uniquely rare cancer-focused meetings speed scientific advances across rare cancers and spark new progress towards precision treatments.
